CAS NO: | 34240-05-6 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 265.23 |
---|---|
Formula | C10H11N5O4 |
CAS No. | 34240-05-6 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 19 mg/mL (71.6 mM) |
Water: 3 mg/mL (11.3 mM) | |
Ethanol: < 1 mg/mL | |
Solubility (In vivo) | |
Synonyms | ADOX |
SMILES Code |
In Vitro | In vitro activity: Adenosine dialdehyde acts as an indirect inhibitor that can be incorporated by cells. The inhibition of S-adenosyl-L-homocystein hydrolase by ADOX can lead to the accumulation of S-adenosyl-L-homo cystein (Adoicy), a product inhibitor of methyltransferases that utilize S-adenosyl-L-methionine (AdoMet) as the methyl group donor. ADOX inhibited the Tax-activated NF-κB pathway, resulting in reactivation of p53 and induction of p53 target genes. Kinase Assay: Cell Assay: Hela cells are grown in MEM medium supplemented with 10% fetal bovine serum at 37 ℃ in a 5% CO2 incubator. Treatment of cells with ADOX for various time periods was performed. The cells are harvested and washed with phosphate-buffered saline, resuspended in buffer A (phosphate-buffered saline with 5% glycerol, 1 mM sodium EGTA, 1 mM dithiothreitol, 0.5% Triton X-100 and Complete protease inhibitor cocktail). |
---|---|
In Vivo | ADOX exerts a potent inhibitory effect on the in situ growth of established murine neuroblastoma (MNB) tumors, prolongs the life span of tumor bearing mice, and does not suppress hematopoiesis when administered by steady state infusion. ADOX inhibits the replication of L1210 leukemia cells and increased life span approximately 40% when administered i.p. at a dose of 20 mg/kg/day until death. |
Animal model | Murine Neuroblastoma Tumor Model |
Formulation & Dosage | Formulated in DMSO (3.3%, v/v), ethanol (50%, v/v) and saline (46.7%, v/v); 1.5 to 2.5 mg/kg/day; s.c. |
References | Cancer Res. 1987 Jul 15;47(14):3656-61; J Med Chem. 1988 Sep;31(9):1798-804. |